Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
about
Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitorsExposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-GlucuronideThe proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinibSimple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies.Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib TherapyCYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.Ontogeny and sorafenib metabolism.A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemiaContribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronideUptake carriers and oncology drug safety.Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).Drug interactions with sunitinib.Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis TherapyEffect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs.BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer.Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.Carbon dioxide-mediated generation of hybrid nanoparticles for improved bioavailability of protein kinase inhibitors.Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.Personalized medicine in oncology: where have we come from and where are we going?Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib.
P2860
Q28236180-C808A67C-4724-4E85-A933-68637376A191Q33411001-F01C6C53-FC11-4825-A392-8D823DA41AFCQ33418378-704355AC-107E-4DB6-AB88-E5E094D64E2CQ33749036-A92427A8-F5D8-405D-ADD0-4878758CB895Q33891564-DDBA2E23-DA37-4B0E-8998-311687460081Q34369606-6DF3DDAB-359B-436E-8BD6-37B29435A124Q34377463-7496DAA3-E9F9-4C4F-A98E-D5EDF96E3845Q35023711-88C8265F-4BD0-43D4-845A-6DB61884C9D5Q35115436-10D1AEE9-8894-43EB-85D4-F1B1BDE95421Q35667438-F11F6DC0-4741-4C12-82FD-FB08890EA1A6Q36229161-D2CA7F0E-9077-416B-9742-8A15DADEBE89Q36375706-34C036DF-D336-491A-A0E6-5CE53F812077Q36462972-73D8FC78-A165-48C5-9978-CDCF9FE9449EQ36506987-CC39AA52-DA4D-4CD5-BAB5-22337B305BF3Q36624496-C06289E4-4A12-4E03-A31C-D88929F929B2Q36639038-EC142B80-4C04-47A8-875C-E91CCF7B48F9Q36698681-D2AFFAB1-4DEE-48B6-863A-79D048EA8AF1Q37663396-194E0971-FE03-4CCB-A97A-D8986F9CCE23Q38028411-C0C1D710-A0CE-4217-9B1C-C2BD835D5BF0Q38101883-B94E5955-06EA-4EBC-928C-D41B7214B085Q38176853-13BEF6FF-6D6E-4728-B68E-314CA1FF75CBQ38198997-A3C7F4F3-3575-4330-98D6-D433D19B626AQ38201503-BAF743F5-2695-4A1A-9326-932223F6FFC8Q38261946-FCAF6D58-A230-4D31-A005-E7F2DA7BBD2BQ38391227-E9AD4868-8D7D-4B8D-9239-1C22FCEBA295Q38936104-4128AECA-C666-4F69-BBCA-D17D3A577380Q38937228-CF81E980-44E0-4727-AF35-0F873150C083Q39031326-09017A14-B216-4CBE-91C2-9F4F7E38C064Q39118167-28B9BA91-B3FB-4A9B-B4D9-72DA0D660D31Q39231153-2514DB5A-542D-46D4-803C-D22A2076590AQ39350678-DF7A16B6-E442-4883-8E7A-DD935C231A9EQ39415429-FFDDAD9B-9CA7-4633-92EE-B42A3A34C27DQ39839324-31FD3908-C0C6-4346-A266-425939AF2A0CQ40003126-56EBCD8F-3FD7-416B-90DB-FE286857D9BBQ40213114-A307A530-40C1-45B1-826E-6CA9B1CA5F37Q41092089-79AB45F3-EBF7-481D-B8C0-D9727272231FQ41972013-9DA025C6-8C8D-4897-9330-1CCFB010B139Q43451983-8F2375DF-FB4E-4086-AE91-DFB7C7CA9E71Q44217256-8A036A00-2F23-4C70-BE0F-4BBD125797B3Q45027232-EC5BAA06-292E-4B47-8D61-8FA5B99A49C2
P2860
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Clinical pharmacokinetics of t ...... dines, pyridines and pyrroles.
@en
Clinical pharmacokinetics of t ...... dines, pyridines and pyrroles.
@nl
type
label
Clinical pharmacokinetics of t ...... dines, pyridines and pyrroles.
@en
Clinical pharmacokinetics of t ...... dines, pyridines and pyrroles.
@nl
prefLabel
Clinical pharmacokinetics of t ...... dines, pyridines and pyrroles.
@en
Clinical pharmacokinetics of t ...... dines, pyridines and pyrroles.
@nl
P2093
P2860
P1476
Clinical pharmacokinetics of t ...... dines, pyridines and pyrroles.
@en
P2093
Andreas Lindauer
Friederike Kanefendt
Jürgen Wolf
Oxana Doroshyenko
Paola Di Gion
Ulrich Jaehde
P2860
P304
P356
10.2165/11593320-000000000-00000
P577
2011-09-01T00:00:00Z
P5875
P6179
1007132094